ReviewThe Journal of clinical investigation2025
T cells in cardiac health and disease.
Review in The Journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Immunometabolic Effects of SGLT2 Inhibitors on the Th17/Treg Axis: Mechanisms, Evidence, and Implications for Therapeutic Repurposing.Molecular biology reports · 2026Review
- Myocardial immune vulnerability unmasked after treatment with immune checkpoint inhibitors: a case report.European heart journal. Case reports · 2026Article
- Immune Aging is an Independent Risk Factor for Cardiovascular Disease.bioRxiv : the preprint server for biology · 2026Article
- T cells in acute and chronic myocarditis: from diagnosis to treatment.European heart journal · 2026Review
- Cardiac fibroblasts in myocardial injury and heart failure.European heart journal · 2026Review
- Linking Mitochondrial Dysfunction to the Immune Microenvironment in HFpEF: An Integrated Bioinformatics and Experimental Approach.Immunity, inflammation and disease · 2026Article
- Shared TCR Vβ21.3+ T cell immunological signature between MIS-A and MIS-C.Journal of human immunity · 2026Article
- Targeting of Cdc42-Interacting Protein 4-Calcineurin Signalosomes Improves Cardiac Structure and Function After Myocardial Infarction.Journal of the American Heart Association · 2026Article
- Remodeling of Cardiac Macrophage Subsets Serves as a Critical Driver of Early Diabetic Myocardial Injury.Journal of inflammation research · 2026Article
- The CALLY index for risk stratification of advanced cardiovascular-kidney-metabolic syndrome and mortality: a dual-cohort study from NHANES and a real-world clinical setting.Frontiers in medicine · 2026Article
- The metabolic-inflammatory axis in chronic heart failure: integrating the NLR and TyG index for recent-onset atrial fibrillation prediction via machine learning and mediation analysis.Frontiers in endocrinology · 2026Article
- Article
- Precision immunomodulation of viral myocarditis: a spatiotemporal intervention paradigm based on smart biomaterials.Frontiers in immunology · 2026Review
- Multifaceted mechanisms of unconventional T cells in ischemia-reperfusion injury.Frontiers in immunology · 2026Review
- The role of glucose metabolic reprogramming in myocarditis and advances in therapeutic strategies.Frontiers in cardiovascular medicine · 2026Review
- Immune Mechanisms in Myocardial Remodeling Following Myocardial Infarction: Focusing on Regulatory Networks of T Cell Responses.Journal of inflammation research · 2026Review
- Article
- RNA 5-Methylcytosine Modification in Myocardial Fibrosis.Reviews in cardiovascular medicine · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide, with inflammation playing a pivotal role in its pathogenesis. T lymphocytes are crucial components of the adaptive immune system that have emerged as key mediators in both cardiac health and the development and progression of CVD. This Review explores the diverse roles of T cell subsets, including Th1, Th17, γδ T cells, and Tregs, in myocardial inflammatory processes such as autoimmune myocarditis and myocardial infarction. We discuss the contribution of T cells to myocardial injury and remodeling, with emphasis on specific immune receptors, e.g., CD69, that have a critical role in regulating immune tolerance and maintaining the balance between T cell subsets in the heart. Additionally, we offer a perspective on recent advances in T cell-targeted therapies and their potential to modulate immune responses and improve clinical outcomes in patients with CVD and in heart transplant recipients. Understanding the intricate interplay between T cells and cardiovascular pathology is essential for developing novel immunotherapeutic strategies against CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.